METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT

1 . A therapeutic for treatment of endometrial cancer, the therapeutic comprising:

a first component comprising a cannabis extract (CE) wherein the CE comprises between 50% and 99.9% cannabidiol (CBD) and wherein said first component has a pH of between 3.5 and 6;

a second component comprising a chemotherapeutic agent selected from the group consisting of: paclitaxel, carboplatin, doxorubicin, cisplatin, docetaxel, gemcitabine, capecitabine, and combinations thereof; and

wherein the first component is administered via an oral form, oral mucosal form, intravaginal form, nasal mucosal form, rectal form, or injectable form.

2 . The therapeutic of claim 1 wherein the CE comprises cannabidiolic acid (CBDA) at a concentration of between 0.1% and 10%.

3 . The therapeutic of claim 1 wherein the first component further comprises a carrier and wherein the CE is 50% to 99% of a total weight of the first component.

4 . The therapeutic of claim 1 wherein the CE is a broad spectrum hemp extract (BSHE) or a full spectrum hemp extract (FSHE) and wherein each of the BSHE and FSHE comprises between 60% and 99% by weight of CBD and at least one other cannabinoid at a concentration of 0.1% to 10% by weight wherein the at least one other cannabinoid is selected from the group consisting of:

Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

5 . The therapeutic of claim 1 wherein the CE comprises cannabidiol (CBD) at a concentration of between 60% and 99% and at least one other cannabinoid at a concentration of 0.1% to 10% wherein the at least one other cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

6 . The therapeutic of claim 5 wherein a total concentration of cannabinoids in the CE is between 65% and 99%.

7 . The therapeutic of claim 1 wherein the first component further comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% of a total weight of the first component.

8 . The therapeutic of claim 1 wherein the first component comprises an oil or a fat as a carrier.

9 . A method for treating endometrial cancer, the method comprising:

a. administering an effective amount of a composition comprising a cannabis extract (CE) to a patient wherein the CE comprises between 50% and 99.9% cannabidiol (CBD) and wherein said composition has a pH of between 3.5 and 6;

b. wherein the CE is administered via an oral form, oral mucosal form, intravaginal form, nasal mucosal form, rectal form, injectable form, or combinations thereof; and

c. administering an effective amount of a chemotherapeutic agent to the patient.

10 . The method of claim 9 wherein the CE comprises cannabidiolic acid (CBDA) at a concentration of between 0.1% and 10%.

11 . The method of claim 9 wherein the composition further comprises a carrier and wherein the CE is 50% to 99% of a total weight of the composition.

12 . The method of claim 9 wherein the CE is a broad spectrum hemp extract (BSHE) or a full spectrum hemp extract (FSHE) and wherein each of the BSHE and FSHE comprises between 60% and 99% by weight of CBD and at least one other cannabinoid at a concentration of 0.1% to 10% by weight wherein the at least one other cannabinoid is selected from the group consisting of:

Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

13 . The method of claim 9 wherein the CE comprises cannabidiol (CBD) at a concentration of between 60% and 99% and at least one other cannabinoid at a concentration of 0.1% to 10% wherein the at least one other cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

14 . The method of claim 13 wherein a total concentration of cannabinoids in the CE is between 65% and 99%.

15 . The method of claim 9 wherein the composition further comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% of a total weight of the composition.

16 . The method of claim 9 wherein the composition comprises an oil or a fat as a carrier.